Development of an algorithm for predicting the risk of cough development during enalapril therapy in patients with arterial hypertension
- Authors: Sychev I.V.1, Denisenko N.P.1, Lapshtaeva A.V.2, Kachanova A.A.1, Abdullaev S.P.1, Kupriyanov Y.Y.2, Goncharova L.N.2, Mirzaev K.B.1, Sychev D.A.1
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- Ogarev Mordovia State University
- Issue: Vol 31, No 9 (2024)
- Pages: 150-154
- Section: Коморбидность
- URL: https://journals.eco-vector.com/2073-4034/article/view/680155
- DOI: https://doi.org/10.18565/pharmateca.2024.9.150-154
- ID: 680155
Cite item
Open Access
Access granted
Abstract
Background. Angiotensin-converting enzyme inhibitors (ACE inhibitors), in particular enalapril, have retained a leading role in the treatment of arterial hypertension (AH) over the past decades, but at the same time have a side effect in the form of cough, which is one of the main reasons for a significant decrease in the quality of life of patients and subsequent drug withdrawal. An important clinical task is to create an algorithm for predicting the risk of cough development for personalizing enalapril therapy.
Objective. Creation of an algorithm for predicting the risk of cough development while taking enalapril for personalizing ACE inhibitor therapy in hypertensive patients.
Methods. To create an algorithm for predicting the risk of cough development while taking enalapril, multivariate modeling was performed using the logistic regression method.
Results. During the multivariate logistic regression analysis, genetic factors were selected in the form of rs2306283 SLCO1B1, rs495828 ABO, rs8176746 ABO gene polymorphisms, as well as data on the presence of allergic diseases and manifestations in close relatives, which together formed a model for predicting the risk of cough development while taking enalapril in hypertensive patients.
Conclusion. The presented model demonstrates high prognostic significance, has sufficient information content (R2=0.31) and allows to predict the development of cough while taking enalapril with an accuracy of 76.5%.
Full Text
About the authors
I. V. Sychev
Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: sychev_iv@bk.ru
ORCID iD: 0000-0003-0227-2651
SPIN-code: 5162-3779
Junior Researcher, Research Institute of Molecular and Personalized Medicine
Russian Federation, MoscowN. P. Denisenko
Russian Medical Academy of Continuous Professional Education
Email: sychev_iv@bk.ru
ORCID iD: 0000-0003-3278-5941
SPIN-code: 5883-6249
Russian Federation, Moscow
A. V. Lapshtaeva
Ogarev Mordovia State University
Email: sychev_iv@bk.ru
ORCID iD: 0000-0003-4828-2476
SPIN-code: 9138-6257
Russian Federation, Saransk
A. A. Kachanova
Russian Medical Academy of Continuous Professional Education
Email: sychev_iv@bk.ru
ORCID iD: 0000-0003-3194-4410
SPIN-code: 1214-8156
Russian Federation, Moscow
Sh. P. Abdullaev
Russian Medical Academy of Continuous Professional Education
Email: sychev_iv@bk.ru
ORCID iD: 0000-0001-9001-1499
SPIN-code: 1727-2158
Russian Federation, Moscow
Yu. Yu. Kupriyanov
Ogarev Mordovia State University
Email: sychev_iv@bk.ru
ORCID iD: 0000-0002-4993-5515
SPIN-code: 7488-1830
Russian Federation, Saransk
L. N. Goncharova
Ogarev Mordovia State University
Email: sychev_iv@bk.ru
ORCID iD: 0000-0002-4324-9071
SPIN-code: 5684-9502
Russian Federation, Saransk
K. B. Mirzaev
Russian Medical Academy of Continuous Professional Education
Email: sychev_iv@bk.ru
ORCID iD: 0000-0002-9307-4994
SPIN-code: 8308-7599
Russian Federation, Moscow
D. A. Sychev
Russian Medical Academy of Continuous Professional Education
Email: sychev_iv@bk.ru
ORCID iD: 0000-0002-4496-3680
SPIN-code: 4525-7556
Russian Federation, Moscow
References
- Alcocer L.A., Bryce A., De Padua Brasil D., et al. The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines. Am J Cardiovasc Drugs. 2023;23(6):663–82. doi: 10.1007/s40256-023-00605-5.
- Brugts J. Discontinuation of Angiotensin Converting Enzyme Inhibitors due to Dry Cough: Incidence and Clinical Determinants. Clin Pharmacol Ther. 2019;105(3):563. doi: 10.1002/cpt.1130.
- Vukadinovic D., Böhm M. Response to «Discontinuation of Angiotensin Converting Enzyme Inhibitors Due to Dry Cough: Incidence and Clinical Determinants». Clin Pharmacol Ther. 2019;105(3):564–5. doi: 10.1002/cpt.1129.
- Стуров Н.В., Чельцов В.В., Илларионова Т.С. и др. Ингибиторы ангиотензинпревращающего фермента: неблагоприятные побочные реакции. Вестник РУДН, серия Медицина. 2004;3(27):28–33. [Sturov N.V., Cheltsov V.V., Illarionova T.S., et al. Angiotensin-converting enzyme inhibitors: adverse adverse reactions. Bulletin of PFUR, series Medicine 2004;3(27):28–33. (In Russ.)].
- Trovato D.A., Sousa J.E., Bruetman J.E., et al. Fracturas costales simetricas asociadas a tos [Symmetrical rib fractures associated with chronic cough. Report of one case]. Rev Med Chil. 2018;146(3):391–3. doi: 10.4067/s0034-98872018000300391.
- Tebha S.S., Zaidi Z.A., Sethar S., et al. Angiotensin converting enzyme inhibitor associated spontaneous herniation of liver mimicking a pleural mass: A case report. World J Hepatol. 2022;14(4):854–9. doi: 10.4254/wjh.v14.i4.854.
- Lee Y.J., Chiang Y.F., Tsai J.C. Severe nonproductive cough and cough-induced stress urinary incontinence in diabetic postmenopausal women treated with ACE inhibitor. Diab Care. 2000:23(3):427–8. doi: 10.2337/diacare.23.3.427.
- Teklay G., Gebremedhin A., Ayalew E. Prevalence of cough among patients treated with angiotensin converting enzyme inhibitors. Int J Pharma Sci Res. 2014;5(12):992–8.
- Корнилов А.А., Глушкова Н. Особенности фармакоэпидемиологии ингибиторов ангиотензинпревращающего фермента на примере регионального фармацевтического рынка. Мировая наука. 2021;6(51):398–401. [Kornilov A.A., Glushkova N. Features of pharmacoepidemiology of angiotensin-converting enzyme inhibitors on the example of the regional pharmaceutical market. World Sci. 2021;6(51):398–401. (In Russ.)].
- Sychev I.V., Denisenko N.P., Kachanova A.A., et al. Pharmacogenetic predictors of development of secondary to enalapril dry cough in hypertensive patients. Drug Metab Personal Ther. 2023;38(3):247–54. doi: 10.1515/dmpt-2023-0008.
- Сычев И.В., Денисенко Н.П., Качанова А.А. и др. Клинико-анамнестические предикторы развития сухого кашля у пациентов с кардиоваскулярной патологией на фоне приема эналаприла. Безопасность и риск фармакотерапии. 2023;11(2):231–40. [Sychev I.V., Denisenko N.P., Kachanova A.A., et al. Clinical Signs and Medical History as Predictors of Enalapril-Associated Dry Cough in Cardiovascular Patients. Safety Risk Pharmacother. 2023;11(2):231–40. (In Russ.)]. doi: 10.30895/2312-7821-2023-11-2-231-240.
Supplementary files
